Please login to the form below

CRPC

This page shows the latest CRPC news and features for those working in and with pharma, biotech and healthcare.

The majority of patients diagnosed with CRPC already present with metastases at time of diagnosis.

Novartis announces positive phase 3 results for prostate cancer drug Pluvicto

The majority of patients diagnosed with CRPC already present with metastases at time of diagnosis.
Pfizer’s Talzenna combination treatment meets primary endpoint in phase 3 prostate cancer study

mCRPC, non-metastatic CRPC, and mCSPC.
AZ/Merck's Lynparza improves survival in certain prostate cancers

CRPC, and a 52% prostate-specific antigen (PSA) response.
Exelixis bounces back with new prostate cancer data

The COSMIC-021 trial evaluated the combination treatment in patients with locally advanced or metastatic castration-resistant prostate cancer (CRPC), whose disease had progressed on prior novel hormone therapy. ... Exelixis intends to file the
Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer

First approval could give Clovis an opportunity to build familiarity with its brand among clinicians treating CRPC before its big pharma rivals reach the market, although its rivals are hot on ... the first half of 2020, while GSK/J&J have also reported

More from news
Approximately 1 fully matching, plus 45 partially matching documents found.

Drug launches to watch in 2019

In patients with non-metastatic CRPC, there is a high unmet need to delay development of metastases and the progression to advanced prostate cancer. ... for approval in the US and EU for non-metastatic CRPC on the strength of MFS data from the PROSPER

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Associate Director - Global Healthcare Consulting: Highly competitive salary

Early Access Program - Regulatory Affairs (EAP-RA): Highly competitive salary

Add my company

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Virtual Patient Engagement Program: A Customer Story: Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?: Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
Rare diseases: not so rare after all: The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...

Email:
Password: